Propranolol Dose Escalation in Lymphedema in Patients

• Status: Terminated
• Trial end date: 2020-10-08
• Target enrollment: 0
• Participant gender: All

Summary

This is a study to investigate the safety and efficacy of propranolol in the treatment of patients with primary lymphedema. The primary goal is to assess patient tolerability of increasing doses of propranolol. The secondary goal is to assess lymphedema symptoms and signs in response to propranolol treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Columbia University
• Treatments: Propranolol

Criteria

Inclusion Criteria:

• Primary lymphedema

• Measurable disease

• Adequate functional status: Karnofsky >50% (>age 16), Lanky >50 (- No prior therapy within 4 weeks of enrollment

• Adequate bone marrow, renal function, cardiac, and pulmonary function, negative pregnancy test (for women).

Exclusion Criteria:

• Secondary lymphedema

• Patients already receiving other investigational drugs

• Patients with known contraindications to receiving propranolol

• Other medical comorbidities including but not limited to: pheochromocytoma, bradycardia, bronchospasm/reactive airway disease, decompensated heart failure, heart block, ongoing active infections.